First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for …

H Ishihara, K Omae, Y Nemoto, R Ishiyama… - International Journal of …, 2024 - Springer
Background There are few comparative studies on dual immune checkpoint inhibitors
(ICIs)(ie, IO-IO) and combination therapies comprising ICIs plus tyrosine kinase inhibitors …
相关文章

First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for …

H Ishihara, K Omae, Y Nemoto… - … journal of clinical …, 2024 - pubmed.ncbi.nlm.nih.gov
Background There are few comparative studies on dual immune checkpoint inhibitors
(ICIs)(ie, IO-IO) and combination therapies comprising ICIs plus tyrosine kinase inhibitors …

First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for …

H Ishihara, K Omae, Y Nemoto, R Ishiyama… - … Journal of Clinical …, 2024 - europepmc.org
There are few comparative studies on dual immune checkpoint inhibitors (ICIs)(ie, IO-IO)
and combination therapies comprising ICIs plus tyrosine kinase inhibitors (TKIs)(ie, IO-TKI) …